TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
Brief Summary: The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia


Options:
A: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
D: Arm Label: Cariprazine 3mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 6mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Aripiprazole 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 3mg, Cariprazine 6mg | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: tivozanib (AV-951); Type: EXPERIMENTAL; Interventions: Drug: tivozanib (AV-951) | Arm Label: sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: tivozanib (AV-951); Assigned to Arm(s): tivozanib (AV-951) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib
B: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
C: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
D: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
B: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: Sunitinib 4/2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib 4/2 | Arm Label: Sunitinib 2/1; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 2/1; Assigned to Arm(s): Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 4/2; Assigned to Arm(s): Sunitinib 4/2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Arm 1
C: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Brief Summary: Primary Objective(s):

* To assess the safety of Replagal at a dose of 0.2 mg/kg administered over 40 (+/-10) minutes in children with Fabry disease
* To assess the effect of Replagal on heart rate variability in patients 7 to 17 years of age

Secondary Objective(s):

* To determine the pharmacokinetics of Replagal at baseline and after the initiation of enzyme replacement therapy (ERT)
* To determine exploratory measurements of efficacy including renal function (ie, estimated glomerular filtration rate \[eGFR\] and creatinine clearance), clinical outcomes (in Cohorts 1 and 2), and sweating and left ventricular mass index (LVMI) (Cohort 1, Phase 1 only)


Options:
A: Arm Label: Fabrazyme; Type: EXPERIMENTAL; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Fabrazyme (agalsidase beta); Type: ACTIVE_COMPARATOR; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fabrazyme 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Arm Label: Fabrazyme 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 0.5 mg/kg | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 1.0 mg/kg
D: Arm Label: Agalsidase alfa (Cohort 1); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Arm Label: Agalsidase Alfa (Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Intervention Type: DRUG; Name: Agalsidase alfa; Assigned to Arm(s): Agalsidase Alfa (Cohort 2), Agalsidase alfa (Cohort 1)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Brief Summary: The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B
C: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: All subjects; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): All subjects

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Brief Summary: The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Brief Summary: The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept/placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: etanercept/placebo; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept (Enbrel) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Etanercept (Enbrel); Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline
B: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
C: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
D: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Arm Label: Internet-based JIA Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Teens Taking Charge | Arm Label: Attention Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management | Intervention Type: BEHAVIORAL; Name: Teens Taking Charge; Assigned to Arm(s): Internet-based JIA Self-Management Program | Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): Attention Control Group
B: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
C: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline
D: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)

Answer: B